哮喘表型和2型炎症哮喘研究进展  

Research progress on the concept discrimination and treatment of type 2 inflammation in asthma

作　　者：时旭[1] 陈如冲[1] 李靖[1] Shi Xu;Chen Ruchong;Li Jing(Department of Allergy and Clinical Immunology,the First Affiliated Hospital of Guangzhou Medical University,National Center for Respiratory Medicine,National Clinical Research Center for Respiratory Disease,State Key Laboratory of Respiratory Disease,Guangzhou Institute of Respiratory Health,Guangzhou 510120,China)

机构地区：[1]广州医科大学附属第一医院变态反应科/国家呼吸医学中心/国家呼吸系统疾病临床医学研究中心/呼吸疾病全国重点实验室/广州呼吸健康研究院,广州510120

出　　处：《结核与肺部疾病杂志》2024年第5期489-494,共6页Journal of Tuberculosis and Lung Disease

基　　金：国际(地区)合作与交流项目(82161138020)。

摘　　要：支气管哮喘(简称“哮喘”)是一种异质性疾病,根据临床特征、触发因素、气道炎症、生理及病理特征等差异存在多种表型。全球哮喘防治倡议(GINA)指南提出哮喘存在2型炎症,并可通过检测嗜酸性粒细胞、呼出气一氧化氮和过敏原等方法诊断2型炎症型哮喘。现已发现50%~70%的哮喘患者与2型炎症有关,中国超过75%的重度哮喘患者存在2型炎症,因此,针对2型炎症哮喘的药物研发和治疗至关重要。作者针对2型炎症哮喘的概念、分类、发病机制、生物标志物及判断标准,以及靶向治疗的研究进展进行综述,为哮喘诊断和生物制剂的治疗提供借鉴。Bronchial asthma(asthma)is a heterogeneous disease with multiple phenotypes based on differences in clinical features,triggers,airway inflammation,physiological and pathological features.The Global Initiative for Asthma(GINA)guidelines suggest that type 2 inflammation exists in asthma and can be diagnosed by testing for eosinophils,exhaled nitric oxide,and allergens.It has been found that 50%to 70%of asthma patients are related to type 2 inflammation,and the proportion of type 2 inflammation in severe asthma patients in China is more than 75%.Therefore,drug development and treatment for type 2 inflammation are critical.The authors review the concept,classification,pathogenesis,biomarkers and judgment criteria,asthma and the research progress of targeted therapy of type 2 inflammatory,and provides reference for the diagnostic and treatment of asthma biologics.

关 键 词：炎症介导素类 支气管高反应性 哮喘 生物学标记 

分 类 号：R256.12[医药卫生—中医内科学] R562.25[医药卫生—中医学]